A citation-based method for searching scientific literature

Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
Times Cited: 300



Michèle Rouleau, Anand Patel, Michael J Hendzel, Scott H Kaufmann, Guy G Poirier. Nat Rev Cancer 2010
Times Cited: 892




List of shared articles



Times cited

PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Emily N Risdon, Cindy H Chau, Douglas K Price, Oliver Sartor, William D Figg. Oncologist 2021
9

PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.
Masa Bosnjak, Tanja Jesenko, Bostjan Markelc, Larisa Janzic, Maja Cemazar, Gregor Sersa. Bioelectrochemistry 2021
1

Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises.
Melissa M Pham, Natalie Y L Ngoi, Guang Peng, David S P Tan, Timothy A Yap. Trends Cancer 2021
0

DoE Optimization Empowers the Automated Preparation of Enantiomerically Pure [18F]Talazoparib and its In Vivo Evaluation as a PARP Radiotracer.
Gregory D Bowden, Sophie Stotz, Johannes Kinzler, Christian Geibel, Michael Lämmerhofer, Bernd J Pichler, Andreas Maurer. J Med Chem 2021
0

Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
Junwei Wang, Hui Li, Guangchao He, Zhaoxing Chu, Kewen Peng, Yiran Ge, Qihua Zhu, Yungen Xu. J Med Chem 2020
11